On Monday, Summit Therapeutics Inc (NASDAQ: SMMT) opened higher 4.77% from the last session, before settling in for the closing price of $17.83. Price fluctuations for SMMT have ranged from $2.10 to $33.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -28.65%. Company’s average yearly earnings per share was noted 70.62% at the time writing. With a float of $114.59 million, this company’s outstanding shares have now reached $737.09 million.
The extent of productivity of a business whose workforce counts for 105 workers is very important to gauge. In terms of profitability, gross margin is 385.96%, operating margin of 77226.38%, and the pretax margin is 83760.85%.
Summit Therapeutics Inc (SMMT) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Summit Therapeutics Inc is 84.45%, while institutional ownership is 11.49%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 70.62% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Check out the current performance indicators for Summit Therapeutics Inc (SMMT). In the past quarter, the stock posted a quick ratio of 8.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
The latest stats from [Summit Therapeutics Inc, SMMT] show that its last 5-days average volume of 1.84 million was inferior to 3.44 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 52.61%. Additionally, its Average True Range was 1.21.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 39.18%, which indicates a significant decrease from 71.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.53% in the past 14 days, which was lower than the 114.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.61, while its 200-day Moving Average is $11.86. Now, the first resistance to watch is $19.18. This is followed by the second major resistance level at $19.68. The third major resistance level sits at $20.36. If the price goes on to break the first support level at $18.00, it is likely to go to the next support level at $17.32. Assuming the price breaks the second support level, the third support level stands at $16.82.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
There are currently 737,448K shares outstanding in the company with a market cap of 13.77 billion. Presently, the company’s annual sales total 0 K according to its annual income of -614,930 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -56,250 K.
